التفاصيل البيبلوغرافية
| العنوان: |
Expression of Bcl-2 19-kDa interacting protein 3 predicts prognosis after ampullary carcinoma resection. |
| المؤلفون: |
Fujimoto, Takaaki, Ohtsuka, Takao, Date, Kenjiro, Kimura, Hideyo, Matsunaga, Taketo, Mori, Yasuhisa, Miyasaka, Yoshihiro, Mochidome, Naoki, Oda, Yoshinao, Nakamura, Masafumi |
| المصدر: |
Journal of Hepato -- Biliary -- Pancreatic Sciences; Aug2016, Vol. 23 Issue 8, p489-496, 8p |
| مستخلص: |
Background: An adequate management strategy for ampullary carcinoma (AC), a rare neoplasm, has yet to be determined. The aim of this study was to identify specific molecular markers allowing for the adequate management of AC. Methods: The clinicopathological data of 41 patients who underwent curative resection of AC were reviewed retrospectively. The expression of thymidylate synthase (TS) and Bcl‐2 19‐kDa interacting protein 3 (BNIP3), two sensitive markers for S‐1 and gemcitabine, respectively, was evaluated immunohistochemically. The relationship between the expression levels of these markers and the clinicopathological data were then investigated. Results: The 5‐year overall survival rate in the study population was 62%. In univariate and multivariate analyses, lymph node metastasis, neural invasion, lymphatic invasion, and the high‐level BNIP3 expression were significant predictive factors for a poor postoperative prognosis. Neither TS nor BNIP3 expression were able to predict survival or the disease recurrence rate in patients who received postoperative adjuvant chemotherapy for AC. Conclusions: BNIP3 expression may serve as a prognostic marker for patients with AC, but neither TS nor BNIP3 contributes to the selection criteria for adjuvant chemotherapy for AC, at least with respect to current drug regimens. Highlight Aiming to establish an adequate management strategy for this rare neoplasm, Fujimoto and colleagues demonstrated that expression of Bcl‐2 19‐kDa interacting protein 3 (BNIP3), a sensitive marker for gemcitabine, may serve as a prognostic marker for ampullary carcinoma, although it does not contribute to the selection criteria for adjuvant chemotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Hepato -- Biliary -- Pancreatic Sciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
